Therakind

Focus: Therakind is a UK-based specialty pharmaceutical company founded in 2023, focused on developing targeted therapeutics in critical care and neonatal indications. The company is pre-commercial with a lean pipeline of repositioned assets.

Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Therakind

AI assessmentNot Hiring

No open roles listed right now. Follow Therakind to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Vancomycin

Late Onset Neonatal Sepsis

Phase 2

Clinical Trials (1)

NCT02790996Neonatal Vancomycin Trial

Phase 2

Help build intelligence for Therakind

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape company culture and strategy at a newly founded (2023) specialty pharma company
Involvement in Phase 2-3 programs with clear clinical endpoints in high-need areas (ICU sedation, neonatal sepsis)
Potential for rapid advancement in a lean organization with only 1 advertised role

Watch Out For

Extreme lack of financial transparency—no disclosed funding, revenue, or cash position creates stability uncertainty
Minimal public information: no publications, no FDA warnings tracked, no recent news available, limiting ability to assess organizational competence
Only 1 active job opening suggests either very early stage or slow growth; founded in 2023 with no disclosed employee count raises execution risk

Generated by Claude from Therakind's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clonidine

Sedation in Intensive Care

Phase 3

Clinical Trials (1)

NCT02509273Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 2 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

1 pipeline

Marketed

Pipeline